Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New insights into devastating cattle disease
Trypanosomiasis causes economic hardship through fever, anaemia and weight loss.
Finding could lead to new treatments for African trypanosomiasis.

Researchers at the University of Edinburgh's Roslin Institute have gained fresh insights into the parasite that causes animal African trypanosome (AAT) infection, also known as sleeping sickness.

The study, published in PLOS Pathogens, reveals key differences in the biology of the Trypanosome congolense parasite, which causes infection in animals, compared with the closely related T. brucei, which affects humans.

Scientists hope their findings will lead to new drugs for AAT and support further studies into the T.congolese parasite, which is spread by biting flies and mainly affects cattle in sub-Saharan Africa.

The team also hopes that the findings will explain how drug resistance has hampered efforts to treat the disease. The same drugs have been used to manage infections for decades, and new therapies are urgently needed.

“The scale of animal African trypanosome infections is enormous, causing devastation to livestock, especially for cattle farmers,” explains Professor Liam Morrison of the Roslin Institute. “There are limited treatments available, and drug resistance is a significant problem. This research forms a valuable resource for the T. congolense parasite, which we hope will underpin more research to target this important pathogen.”

Trypanosomiasis is a chronic disease of livestock that causes fever, anaemia and weight loss. The condition is of most importance in cattle, but other animals, including dogs, can also be affected.

“Trypanosomiasis is a major problem for livestock owners in Africa, Asia and Latin America,” explains Michael Pearce from industry partner, GALVmed. “Developing new drug products is costly and it takes many years to develop and register safe and efficacious treatments.

“Understanding the metabolism of parasites such a trypanosomes helps researchers identify candidate molecules with the best chance of translation in to a successful treatment,” he said.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.